Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-transplant rituximab with nonmyeloablative allogeneic hematopoietic cell transplantation for advanced chronic lymphocytic leukemia
2009-015968-34Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and prolymphocytic leukemia (PLL), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: 18-month survival. Started Feb 2010; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on 2009-015968-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015968-34.